Enzychem Lifesciences Corp. (183490) AI Stock Analysis

Enzychem Lifesciences Corp.

(Korea Exchange:183490)

Select Model

Rating:49Neutral

Price Target:KRW 985.00▼(-0.51% Downside)

Action:initiatedcoverage

Date:10/28/26

The score is held down primarily by ongoing losses and worsening cash burn despite a much improved, low-leverage balance sheet. Technical indicators also lean weak (below the 200-day average with low RSI/stochastic), while valuation support is limited because the company is loss-making and no dividend yield is available.

Positive Factors

Conservative LeverageDebt-to-equity of about 0.04 in 2025 indicates a conservative capital structure and materially less leverage than in 2020–2021. This reduces balance-sheet strain and preserves borrowing and investment flexibility while the company works to restore profitability.

Negative Factors

Persistent UnprofitabilityNegative operating and net profit in every year shown, together with deeply negative operating and net margins, demonstrates that the current business model is not yet producing sustainable earnings. This weakens confidence in near-term earnings power and self-funded growth.

Enzychem Lifesciences Corp. (183490) vs. SPDR S&P 500 ETF (SPY)

Market Cap: KRW 76.86B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -8.2
Beta (1Y): -0.14
Revenue Growth: -5.10%
EPS Growth: 19.68%
Country: KR
Employees: ―
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Enzychem Lifesciences Corp. Business Overview & Revenue Model

Company Description

Enzychem Lifesciences Corporation specializes in the creation and manufacturing of active pharmaceutical ingredients (APIs) and specialized nutritional products. Its operations also extend to the production of a diverse range of animal health product...

Enzychem Lifesciences Corp. Financial Statement Overview

Summary

Mixed fundamentals: the balance sheet is relatively strong with very low leverage (debt-to-equity ~0.04), but the company remains unprofitable with consistently negative operating/net margins and a recent revenue decline (~6%). Cash flow is a key weakness, with persistent negative operating/free cash flow and a sharp worsening in 2025 (OCF about -11.0B; FCF about -11.8B).

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	67.75B	67.75B	77.38B	76.04B	26.64B	22.98B
Gross Profit	3.38B	3.38B	4.31B	4.35B	2.42B	286.72M
EBITDA	-8.55B	-14.90B	-18.39B	-5.75B	-13.16B	-17.89B
Net Income	-18.13B	-18.13B	-22.11B	-9.33B	-25.09B	-27.86B
Balance Sheet
Total Assets	148.59B	148.59B	181.74B	211.55B	247.55B	133.08B
Cash, Cash Equivalents and Short-Term Investments	92.82B	92.82B	117.07B	137.35B	192.86B	94.59B
Total Debt	4.84B	4.84B	4.88B	5.66B	37.78B	51.98B
Total Liabilities	9.83B	9.83B	20.26B	16.92B	45.81B	58.42B
Stockholders Equity	137.54B	137.54B	160.35B	193.52B	201.74B	74.66B
Cash Flow
Free Cash Flow	-11.79B	-11.79B	-1.06B	-12.56B	-22.33B	-24.47B
Operating Cash Flow	-11.01B	-11.01B	-573.93M	-10.26B	-14.32B	-18.59B
Investing Cash Flow	11.93B	11.93B	7.36B	53.56B	-109.23B	-9.73B
Financing Cash Flow	-3.34B	-3.34B	-12.14B	-35.50B	128.50B	29.26B

Enzychem Lifesciences Corp. Technical Analysis

Technical Analysis SentimentNegative

Last Price990.00

Price Trends

50DMA990.00Neutral

100DMA990.00Neutral

200DMA1041.30Negative

Market Momentum

MACD-0.00Negative

RSI37.46Neutral

STOCH15.38Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:183490, the sentiment is Negative. The current price of 990.00 is equal to the 20-day moving average (MA) of 990.00, equal to the 50-day MA of 990.00, and below the 200-day MA of 1041.30, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 37.46 is Neutral, neither overbought nor oversold. The STOCH value of 15.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:183490.

Enzychem Lifesciences Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

KR:183490 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KR:069620	61Neutral	KRW 1.16T	5.95	―	0.59%	9.87%	160.28%
KR:249420	60Neutral	KRW 397.78B	8.87	―	1.59%	-0.65%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
KR:068760	54Neutral	KRW 1.59T	130.86	―	0.42%	13.88%	29.24%
KR:183490	49Neutral	KRW 76.86B	-8.16	―	―	-5.10%	19.68%
KR:170900	46Neutral	KRW 322.72B	-55.36	―	2.07%	15.38%	―
KR:003060	40Underperform	KRW 40.05B	-0.23	―	―	26.13%	58.75%

* General Sector Average

Performance Comparison

KR:183490 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KR:183490	Enzychem Lifesciences Corp.	990.00	-1.00	-0.10%
KR:003060	Aprogen Biologics	1335.00	-6870.00	-83.73%
KR:068760	Celltrion Pharm Inc.	36650.00	-26478.69	-41.94%
KR:069620	Daewoong Pharmaceutical Co., Ltd.	101100.00	-41905.73	-29.30%
KR:170900	Dong-A ST Co., Ltd.	33850.00	-12411.18	-26.83%
KR:249420	Ildong Pharmaceutical Co., Ltd.	12580.00	-14837.52	-54.12%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

Enzychem Lifesciences Corp. AI Stock Analysis